Company Overview of Celladon Corporation
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...
11988 El Camino Real
San Diego, CA 92130
Founded in 2000
Key Executives for Celladon Corporation
Chief Executive Officer and Director
Total Annual Compensation: $479.3K
President and Chief Financial Officer
Total Annual Compensation: $189.7K
Vice President, General Counsel and Secretary
Total Annual Compensation: $233.8K
Vice President of Corporate Development & Investor Relations
Total Annual Compensation: $190.4K
Vice President of Corporate Operations
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2014.
Celladon Corporation Key Developments
Celladon Corporation Announces Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 14 15
Celladon Corporation announced un-audited consolidated earnings results for the first quarter ended March 31, 2015. The company reported loss from operations of $16.3 million compared to $6.9 million and net loss of $16.7 million compared to $7.2 million for the last year.
Celladon Explores Strategic Options
May 14 15
Celladon Corporation (NasdaqGM:CLDN) is exploring strategic options. Krisztina Zsebo, Chief Executive Officer of Celladon, said, "We are evaluating our strategic options in order to determine the best path forward to maximize shareholder value."
Celladon Corporation - Special Call
Apr 27 15
To discuss negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries